stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs Insmed, Inc. (INSM)
- Alnylam Pharmaceuticals, Inc. ALNY 157.11 +0.29%
- Insmed, Inc. INSM 110.17 +1.30%
Alnylam Pharmaceuticals, Inc. and Insmed, Inc. are both Biotechnology companies. Insmed, Inc. is the larger, with a market value of $23.9B against $21.0B — 1.1× the size. Insmed, Inc. has negative trailing earnings, so its P/E is not meaningful; Alnylam Pharmaceuticals, Inc. trades at 7.9×. Insmed, Inc. grew revenue faster over the last twelve months: 240.0% against 56.2%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs −39.9%) and the higher return on invested capital (59.4% vs −247.6%). Across the 18 metrics below, Alnylam Pharmaceuticals, Inc. leads on 15 and Insmed, Inc. on 3.
Valuation
Profitability
| Metric | ALNY | INSM | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 84.40% | 65.16% |
| Operating margin | 19.50% | (37.11%) | 0.00% |
| Net margin | 52.85% | (39.85%) | 0.00% |
| Free cash flow margin | 16.08% | (41.30%) | 0.00% |
| Return on equity | 138.07% | (72.45%) | (50.12%) |
| Return on assets | 41.25% | (26.41%) | (45.60%) |
| Return on invested capital | 59.37% | (247.55%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack